Creative Planning
PLX icon

Creative Planning’s Protalix BioTherapeutics PLX Stock Holding History

Creative Planning’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.04M Buy
+375,359
New +$934K ﹤0.01% 2728
2025
Q2 		– Sell
-32,740
Closed -$83.8K – 3772
2025
Q1 		$83.8K Buy
+32,740
New +$78.2K ﹤0.01% 3276

Other funds holding PLX

STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Bailard
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Ashton Thomas Private Wealth
Ashton Thomas Private Wealth Scottsdale, Arizona $4.98B AUM 21.09% 1-Year Est. Return
OGF
Orin Green Financial San Diego, California $267M AUM 12.91% 1-Year Est. Return
Kestra Advisory Services
Kestra Advisory Services Austin, Texas $35.1B AUM 20.13% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Creative Planning's PLX Position: Q3 2026 in Review

Creative Planning opened a new position in Protalix BioTherapeutics (PLX) in Q3 2026: 375,359 shares worth $1.04M. The stake represents ﹤0.01% of the portfolio and ranks #2728 among its holdings. This is a return to the name: Creative Planning previously reported a position in PLX as recently as Q1 2025.

Creative Planning first reported a position in PLX in Q1 2025 and has held it in 2 quarters since. 23 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

  • Creative Planning held 375,359 shares of Protalix BioTherapeutics worth $1.04M as of Q3 2026.
  • Protalix BioTherapeutics was a new Creative Planning position in Q3 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of Creative Planning's portfolio in Q3 2026, its #2728 holding.
  • Creative Planning first reported a position in Protalix BioTherapeutics in Q1 2025 and has held it in 2 quarters since.
  • 23 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on Creative Planning's 13F filing for Q3 2026, filed 2 Nov 2026.